Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus
New York, February 7, 2026, 05:48 EST — Market closed
- Pfizer finished Friday up 2.8%, closing at $27.22.
- The FDA put Hympavzi’s label expansion on an expedited review path, aiming for a decision by Q2 2026.
- TrumpRx launches its drug-discount program, dragging the spotlight back onto pricing pressure.
Pfizer Inc (PFE) closed out Friday at $27.22, notching a 2.8% gain. Shares fluctuated from $26.52 to $27.37 throughout the session, with volume hitting roughly 50.7 million shares. 1
Shares got a boost late in the week as Pfizer secured priority review status from the FDA on its supplemental bid for expanded Hympavzi use—a regulatory timer now ticking toward a second-quarter decision. Priority review…
